BeiGene (BGNE) IPO Opens Up 20%

Today's IPO for BeiGene (NASDAQ: BGNE) opened for trading at $28.97 after pricing of its initial public offering of 6,600,000 American Depositary Shares (ADS), each representing 13 of its ordinary shares, par value $0.0001 per share, at an initial public offering price of $24.00 per ADS.

Goldman, Sachs & Co., Morgan Stanley and Cowen and Company are acting as joint book-running managers. Baird is acting as co-manager of the offering.

BeiGene is a global, clinical-stage, research-based biotechnology company focused on targeted and immuno-oncological therapeutics. With a team of 215+ scientists and staff, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is working to create combination solutions aimed to have both a meaningful and a lasting impact on cancer patients.

You May Also Be Interested In

• Anthropic wants to match or beat SpaceX’s record IPO size - report
• EquipmentShare.com Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against EquipmentShare.com Inc. - EQPT
• Satellite maker Muon Space valued at $1.5 billion, source says